Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib and Bortezomib in Solid Tumors and MTC
NCT00923247Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2009
- Primary completion
- Apr 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in medullary thyroid carcinoma (MTC), solid tumor, sponsored by National Cancer Institute. Started Feb 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
medullary thyroid carcinoma (MTC)solid tumor
Beyond the preview
Go deeper on NCT00923247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923247.